[Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review]

Area of Science:

• Oncology
• Immunotherapy
• Genetics

Background:

• Advanced non-small cell lung cancer (NSCLC) with EGFR mutations often develops resistance to tyrosine kinase inhibitors (TKIs).
• Immune checkpoint inhibitors (ICIs) offer a new treatment avenue, but their efficacy in this subgroup is inconsistent.
• Understanding resistance mechanisms and optimizing combination strategies is crucial.

Purpose of the Study:

• To investigate the efficacy of different immune checkpoint inhibitor (ICI) combination therapies in advanced NSCLC patients with EGFR mutations who are resistant to TKIs.
• To identify factors influencing treatment efficacy and their relationship with predictive biomarkers.
• To explore novel therapeutic strategies in the era of immunotherapy.

Main Methods:

• Review of existing studies on ICI combination therapy in EGFR-mutated NSCLC with TKI resistance.
• Analysis of patient subgroups based on driver gene status and resistance profiles.
• Exploration of predictive biomarkers for immunotherapy response.

Main Results:

• Efficacy of ICI combination therapy varies significantly among different patient subgroups.
• Specific driver gene profiles and resistance mechanisms correlate with treatment outcomes.
• Interactions between predictive biomarkers and combination strategies require further elucidation.

Conclusions:

• Optimizing ICI combination therapy for EGFR-mutated NSCLC with TKI resistance necessitates personalized approaches.
• Further research is needed to refine patient selection and identify novel predictive biomarkers.
• Tailoring immunotherapy strategies holds significant promise for improving patient outcomes.